Argent Biopharma (AU:RGT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Argent BioPharma is set to delist from the London Stock Exchange by the end of December 2024, focusing its listing efforts on the Australian Securities Exchange and the OTCQB Venture Market. This strategic move aims to streamline operations and boost administrative efficiency while keeping the door open for potential U.S. market opportunities. Investors should prepare for the last trading day on the LSE and consult advisors for future trading options.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
